Professor of Clinical Biochemistry
- Finland Distinguished Professor (Adjunct), BoMediTech, University of Tampere
- Attending Clinical Chemist (part-time), MSKCC
- Professor (Adjunct), Lund University
My research focuses on the biology of prostate-secreted kallikrein-related peptidases and microseminoprotein-beta (MSMB) and their association with risk and phenotype outcome of prostate cancer.
During my PhD thesis-project at Lund University, I studied the function of the male accessory sex glands. This led to my discovery of the physiological function of prostate-specific antigen (PSA). Based on the hypothesis that the biomarker function of PSA is contingent on the catalytic action of PSA, I discovered that the free, unbound PSA in blood was an independent predictor of prostate cancer risk and that PSA was mainly bound to alpha-1-antichymotrypsin in blood. I went on to combine basic, translational, and clinical research to investigate the biology and regulation of the catalytic action of PSA and related biomarkers, their association with risk, phenotype, and prostate cancer outcome.
I have published 284 peer-reviewed original research reports and 66 peer-reviewed review papers and have the experience and expertise to serve as Co-Leader of research project 5 on the proposed SPORE in Prostate Cancer.
Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy.
Wu X. et al, (2019), Prostate, 79, 1079 - 1089
The role of plasma microseminoprotein-beta in prostate cancer: an observational nested case-control and Mendelian randomization study in the European prospective investigation into cancer and nutrition.
Smith Byrne K. et al, (2019), Ann Oncol
Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.
Preston MA. et al, (2019), Eur Urol, 75, 399 - 407
Reply to Kathryn L. Penney, Massimo Loda, and Meir J. Stampfer's Letter to the Editor re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. Eur Urol 2018;73:961-7.
Vickers AJ. et al, (2019), Eur Urol, 75
A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.
Hugosson J. et al, (2019), Eur Urol